Status:
RECRUITING
Therapy Management in Patients Treated With Anakinra Due to Recurrent Pericarditis
Lead Sponsor:
Azienda Ospedaliero, Universitaria Ospedali Riuniti
Conditions:
Recurrent Pericarditis
Eligibility:
All Genders
Phase:
NA
Brief Summary
To determine the utility of serial cardiac magnetic resonance (CMR) imaging for guidance of therapy management in patients treated with anakinra due to recurrent pericarditis (RP), compared with c-rea...
Detailed Description
Recurrent pericarditis (RP) is a specific pathology of the pericardium included within the pericardial syndromes by the guidelines of the European Society of Cardiology (ESC). The latter defines RP as...
Eligibility Criteria
Inclusion
- Adult patients treated with anakinra 100 mg/die if ≥ 18 years old, and
- Pediatric patients treated with anakinra 2 mg/kg/die if \< 18 years old
- Pediatric and adult patients treated with anakinra due to corticosteroid-dependent or not responsive to colchicine or non-steroidal anti-inflammatory drugs (NSAIDs) recurrent pericarditis
Exclusion
- Ongoing infection (proved within serology)
- Refuse to participate in the trial
Key Trial Info
Start Date :
January 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 31 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06071156
Start Date
January 1 2018
End Date
January 31 2025
Last Update
April 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CCPC
Ancona, The Marches, Italy, 60123